Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Baden-Baden – page 62

1 153 clinical trials in Baden-Baden, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Baden-Baden at a glance
1 153
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 153 trials in Baden-Baden

Open in trial search

Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:Diphtheria toxoid
  • Sponsor:Sanofi Pasteur Inc.

Title: Study of LP352 (bexicaserin) oral solution versus placebo for treating seizures in children and adults with Developmental and Epileptic Encephalopathies

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bexicaserin hydrochloride
  • Sponsor:Longboard Pharmaceuticals Inc.

Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Coronavirus infection

Not recruiting

Study on COVID-19 Prevention Using Sipavibart and Cilgavimab for Patients with Weakened Immune Systems

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Cilgavimab
  • Sponsor:AstraZeneca AB

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal oligosaccharide serotype 18C conjugated to CRM197
  • Sponsor:Sanofi Pasteur Inc.

Study on the Safety and Immune Response of MenABCWY Vaccine in Healthy Adolescents Aged 11-14 with Meningococcal Meningitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
  • Sponsor:Sanofi Pasteur

Premature ejaculation

Not recruiting

Study on the Effectiveness of BP1.4979 for Adult Men with Premature Ejaculation

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:BP1.4979
  • Sponsor:Bioprojet Pharma

Myasthenia gravis

Not recruiting

Study on the Effects of Remibrutinib for Patients with Generalized Myasthenia Gravis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Celgene Corp.

Study on the Effects of Bexicaserin for Treating Seizures in Children and Adults with Dravet Syndrome

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bexicaserin hydrochloride
  • Sponsor:Longboard Pharmaceuticals Inc.

Study on the Safety and Effects of NVG-2089 for Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:NVG-2089
  • Sponsor:Nuvig Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Baden-Baden

What the registry says about research in the country

01 Eye Diseases and Ocular Physiology

Clinical research in Baden-Baden includes studies focused on eye diseases and ocular physiological phenomena, with attention on atrophic age-related macular degeneration. These trials are exploring ways to slow disease progression and better understand vision-related decline.

  • Testing a new approach for geographic atrophy linked to AMD
  • Evaluating treatment effectiveness in progressive retinal disease

The goal is to improve care for patients facing gradual loss of vision through more effective targeted therapies.

02 Neoplasms in Breast Cancer Research

A major part of the clinical trial activity in the city centers on breast cancer, including HER2+, HR+/HER2-, and triple-negative early breast cancer. These studies are examining new treatment combinations to strengthen disease control and improve long-term outcomes.

  • Assessing new therapy combinations for HER2+ early breast cancer
  • Comparing treatment strategies in HR+/HER2- early breast cancer
  • Studying options for triple-negative early breast cancer

Research in this area is aimed at improving response rates and reducing the chance of recurrence after initial treatment.

03 Hemic and Lymphatic Diseases

Trials in hematologic malignancies are investigating new strategies for patients with high-risk chronic lymphocytic leukemia. The focus is on whether newer drug combinations can offer stronger disease control than current standard approaches.

  • Evaluating combination treatment for high-risk CLL
  • Studying outcomes in patients with adverse genetic risk factors

These studies are designed to improve progression control and support more personalized treatment choices.

04 Ovarian and Gynecologic Cancer

Another active research area involves advanced ovarian cancer and related gynecologic cancers, including fallopian tube cancer, primary peritoneal cancer, and clear cell carcinoma of the ovary. The trials are examining treatment strategies for patients with no visible residual tumor after surgery.

  • Studying maintenance approaches in HRD-positive high-grade ovarian cancer
  • Evaluating recurrence prevention after primary tumor debulking

These efforts aim to extend recurrence-free survival and refine post-surgical treatment planning.

05 Personalized Oncology in Early Breast Cancer

Several studies are exploring personalized cancer therapy for early-stage breast cancer, using treatment selection to match individual risk profiles. This includes approaches that combine targeted medicine, endocrine therapy, and other systemic treatments.

  • Testing personalized treatment for intermediate- to high-risk HR+/HER2- breast cancer
  • Comparing targeted therapy with standard adjuvant care
  • Improving invasive disease-free survival in early cancer care

In Baden-Baden, this line of research reflects a broader move toward more tailored and effective cancer treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.